Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma by Mollica, Veronica et al.
  
Cancers 2020, 12, 1449; doi:10.3390/cancers12061449 www.mdpi.com/journal/cancers 
Review 
Current Strategies and Novel Therapeutic 
Approaches for Metastatic Urothelial Carcinoma 
Veronica Mollica 1,2,†, Alessandro Rizzo 1,2,†, Rodolfo Montironi 3, Liang Cheng 4,  
Francesca Giunchi 5, Riccardo Schiavina 6, Matteo Santoni 7, Michelangelo Fiorentino 8,  
Antonio Lopez-Beltran 9, Eugenio Brunocilla 6, Giovanni Brandi 1,2 and Francesco Massari 1,* 
1 Division of Oncology, S.Orsola-Malpighi Hospital, 40138 Bologna, Italy; veronica.mollica7@gmail.com 
(V.M.); rizzo.alessandro179@gmail.com (A.R.); giovanni.brandi@unibo.it (G.B.) 
2 Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital,  
40138 Bologna, Italy 
3 Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United 
Hospitals, 60121 Ancona, Italy; r.montironi@staff.univpm.it 
4 Department of Pathology and Laboratory Medicine, Indiana University School of Medicine,  
Indianapolis, IN 46202, USA; liang_cheng@yahoo.com 
5 Pathology Service, Addarii Institute of Oncology, S-Orsola-Malpighi Hospital, 40138 Bologna, Italy; 
frachikka@virgilio.it 
6 Department of Urology, University of Bologna, S-Orsola-Malpighi Hospital, 40138 Bologna, Italy; 
riccardo.schiavina3@unibo.it (R.S.); eugenio.brunocilla@unibo.it (E.B.) 
7 Oncology Unit, Macerata Hospital, 62100 Macerata, Italy; mattymo@alice.it 
8 Department of Pathology, University of Bologna, School of Medicine, 40126 Bologna, Italy; 
michelangelo.fiorentino@unibo.it 
9 Unit of Anatomical Pathology, Faculty of Medicine, Cordoba University, 14071 Cordoba, Spain; 
eugenio.brunocilla@unibo.it 
* Correspondence: fmassari79@gmail.com; Tel.: +39-051-214-2575 
† These authors contribution is equally to this work. 
Received: 21 May 2020; Accepted: 1 June 2020; Published: 2 June 2020 
Abstract: Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. 
Metastatic UC has been historically associated with poor prognosis, with a median overall survival 
of approximately 15 months and a 5-year survival rate of 18%. Although platinum-based 
chemotherapy remains the mainstay of medical treatment for patients with metastatic UC, 
chemotherapy clinical trials produced modest benefit with short-lived, disappointing responses. In 
recent years, the better understanding of the role of immune system in cancer control has led to the 
development and approval of several immunotherapeutic approaches in UC therapy, where 
immune checkpoint inhibitors have been revolutionizing the treatment of metastatic UC. Because 
of a better tumor molecular profiling, FGFR inhibitors, PARP inhibitors, anti-HER2 agents, and 
antibody drug conjugates targeting Nectin-4 are also emerging as new therapeutic options. 
Moreover, a wide number of trials is ongoing with the aim to evaluate several other alterations and 
pathways as new potential targets in metastatic UC. In this review, we will discuss the recent 
advances and highlight future directions of the medical treatment of UC, with a particular focus on 
recently published data and ongoing active and recruiting trials.  
Keywords: urothelial carcinoma; immunotherapy; immune checkpoint inhibitors; FGFR; antibody 
drug conjugates; clinical trials; PD-1; PD-L1 
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1. Introduction 
Urothelial carcinoma (UC) is a common cancer worldwide, with nearly half a million of new 
diagnoses annually [1]. Although UC includes a group of tumors of the bladder, renal pelvis, ureter 
and urethra, more than 90% of UCs occurs in the lower urinary tract, therefore involving urinary 
bladder and, less often, urethra [2]. About 70–75% of patients at diagnosis are affected by 
non-muscle-invasive bladder cancer (NMIBC) while more than 25% of cases are already 
muscle-invasive bladder cancer (MIBC) or metastatic forms [3]. Despite recent improvements in the 
field of medical oncology, the prognosis of patients with advanced or metastatic UC remains dismal, 
with a median overall survival (OS) of approximately 15 months from diagnosis [4]. In the last 
twenty years, front-line cisplatin-based chemotherapy represented the mainstay of palliative 
treatment for UC, with combinations such as gemcitabine plus cisplatin (GC) and methotrexate, 
vinblastine, doxorubicin, and cisplatin (M-VAC) as the cornerstones of standard treatment in 
advanced or metastatic UC [5–7]. Although GC and M-VAC regimens showed similar outcomes in 
terms of OS and time to treatment failure (TTF), GC is commonly preferred over M-VAC on the basis 
of lower mucosal and hematological toxicity [5–7]. Nevertheless, most patients are 
cisplatin-ineligible because of inadequate renal function, poor Eastern Cooperative Oncology Group 
(ECOG) performance status, peripheral neuropathy, old age and/or other underlying comorbidities, 
and thus, cisplatin is usually replaced by carboplatin in unfit patients, as we shall see later [8]. 
Unfortunately, after the failure of first-line treatments, further therapies have yielded poor response 
rates and the overall results obtained with conventional cytotoxic agents (as monotherapy or in 
combination) have been far from being satisfactory since UC patients historically carried a median 
OS of approximately 12–17 months [9]. Thus, there is an urgent need for novel, more effective 
treatment options in advanced or metastatic UC. 
Recent phase I to III studies with drugs targeting immune checkpoints and different molecular 
pathways of UC are ongoing and some were published in the last three years [10]. These novel 
agents primarily include immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs) 
targeting fibroblast growth factor receptor (FGFR), and antibody-drug conjugates (ADCs) directed 
against Nectin-4 [11,12]; however, many other alterations and pathways are also emerging as new 
potential targets [13]. In this paper, we provide a comprehensive review of recent trials and the 
current state of ongoing active and recruiting Phase I, II, and III trials according to clinicaltrial.gov, 
looking into the future of the rapidly evolving landscape of medical treatment for advanced or 
metastatic UC. 
We performed a research on Pubmed/Medline, Cochrane library and Scopus using the keyword 
“urothelial carcinoma“ OR “bladder carcinoma” OR “bladder urothelial carcinoma” OR “bladder 
cancer” OR “bladder neoplasm.” We selected pivotal registration studies. We also selected the most 
relevant and pertinent studies considering quality of the studies in terms of their applicability, how 
they were conducted, statistical analysis, number of patients enrolled, outcomes. For ongoing 
clinical trials, we searched in the clinicaltrials.gov database for recruiting and active, not recruiting 
trials, using the following keywords: “urothelial carcinoma“ OR “bladder carcinoma” OR “bladder 
urothelial carcinoma” OR “bladder cancer” OR “bladder neoplasm.” We restricted our research to 
phase 1, 2, or 3 trials focused on the metastatic/advanced setting. 
2. Treatment Strategies: State-of-the-Art 
2.1. Immune Checkpoint Inhibitors 
The advent of ICIs blocking the interaction of Programmed Death 1 (PD-1) and Cytotoxic 
T-Lymphocyte Antigen 4 (CTLA-4) with their specific ligands has recently revolutionized the 
treatment of several hematological and solid malignancies (Figure 1) [14–16]. Outstandingly, ICIs 
have challenged previous treatment paradigms of most solid tumors, including the therapeutic 
decision-making approach to advanced or metastatic UC, in the first-line setting for 
cisplatin-ineligible patients as well as in the post-platinum setting [17,18]. Given the well-known 
activity of topical instillation of Bacillus of Calmette-Guérin (BCG) in high-risk, non-muscle invasive 
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disease, UC immediately appeared as a suitable candidate for modern immunotherapy [19]; 
moreover, UC is known to be a highly antigenic malignancy, given the high rates of DNA alterations 
and mutations leading to the formation of neoantigens, an element which further supports the 
application of ICIs in advanced or metastatic UC [20–22]. In light of data provided by a variety of 
recent trials, the therapeutic scenario of UC is rapidly changing but, unfortunately, several unmet 
clinical needs still persist [22,23]. 
 
Figure 1. The interaction between PD-1/PD-L1 and CTLA-4/B7-1, a key mechanism exploited by 
immune checkpoint inhibitors. PD-1 inhibitors include nivolumab, pembrolizumab, cemiplimab, 
tislelizumab, and other agents currently in development; conversely, PD-L1 inhibitors encompass 
agents such as atezolizumab, avelumab, durvalumab, while CTLA-4 inhibitors encompass 
ipilimumab and tremelimumab. 
Although cisplatin-based regimens are considered the standard first-line treatment in advanced 
or metastatic UC, more than 50% of patients are ineligible for cisplatin in clinical practice [24]. For 
this non-negligible group of patients, carboplatin plus gemcitabine has been considered the standard 
treatment based on the results of the EORTC 30,986 trial, with several other combinations and agents 
showing less favorable safety profiles and inferior outcomes compared to cisplatin-based first-line 
therapy [25–27]. Thus, the modest survival benefits observed with available treatment options 
highlighted the need for new effective strategies [28] and for this purpose, following small phase I 
trials, the role of ICIs as front-line treatment in cisplatin-ineligible patients was investigated in 
KEYNOTE-052 and IMvigor210 trials [29,30].  
The KEYNOTE-052 [29] was a phase II trial aimed to evaluate the safety and efficacy of 
pembrolizumab monotherapy (200 mg flat dose every three weeks) in 370 chemo-naive, 
cisplatin-ineligible patients. In this setting pembrolizumab, a highly selective humanized 
monoclonal IgG4 isotype antibody against PD-1 protein, produced an overall response rate (ORR) of 
24% with 5% of complete response (CR). Interestingly, the magnitude of ORR and survival benefit 
was related to programmed death ligand-1 (PD-L1) expression: in fact, in patients with PD-L1 
expression combined positive score (CPS) ≥ 10%, pembrolizumab resulted in improved survival, 
with a median OS of 18.5 months versus 11.5 months in overall cohort. Finally, the CPS ≥ 10% 
population reported higher ORR (37%) compared to the CPS < 10% subgroup of patients (ORR = 
18%).  
The IMvigor210 trial [30] was a 2-cohort Phase 2 study; while cohort 2 assessed atezolizumab in 
a post-platinum setting, in cohort 1 the anti-PD-L1 agent was tested as first-line treatment in 
Cancers 2020, 12, 1449 4 of 47 
 
cisplatin-ineligible subjects. Total of 119 untreated patients were included in cohort 1 and received 
atezolizumab, 1200 mg flat dose every three weeks, achieving an ORR of 23% with CR and partial 
response (PR) of 9% and 12% respectively, regardless of PD-L1 expression. Clinical activity of 
atezolizumab was higher than those observed with systemic chemotherapies traditionally used in 
this setting, in respect of whom the anti-PD-L1 agent showed also a more manageable safety profile.  
Based on the aforementioned studies, pembrolizumab and atezolizumab were approved by the 
US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for front-line use 
in cisplatin unfit patients affected by advanced or metastatic UC. However, the use of 
pembrolizumab and atezolizumab has been subsequently restricted, following early data from 
KEYNOTE-361 and IMvigor130 phase III trials which, as we shall explain later, are currently 
investigating combination chemo-immunotherapy in advanced or metastatic UC. In these two trials, 
patients with low expression of PD-L1 receiving single-agent ICI experienced worse survival 
compared to patients receiving standard chemotherapy [31,32]. 
Following platinum-based chemotherapy, large proportions of patients are either 
non-responders or relapsed, and therefore proceed for second-line treatment [33]. Until some years 
ago, taxanes or vinflunine were considered standard second-line treatments, despite disappointing 
ORRs and an overall modest clinical benefit [34,35]. In this scenario, recent results of Phase I to III 
studies with agents targeting PD-1 and PD-L1 have led to fast approval of ICIs as second-line 
treatments. In particular, five ICIs (two anti-PD-1 agents—pembrolizumab and nivolumab—and 
three anti-PD-L1 agents—atezolizumab, durvalumab, and avelumab) have been granted approval 
by FDA for patients with advanced or metastatic UC whose disease progressed during or following 
platinum-based chemotherapy [36]. Conversely, despite FDA has granted approval for the 
aforementioned agents, pembrolizumab is the only ICI that showed a survival benefit in a phase III 
randomized clinical trial and whose activity is supported by higher levels of evidence [37]. 
The approval of pembrolizumab in post-platinum setting was granted based on the results of 
the KEYNOTE-045 trial [38]. This phase III, open-label, randomized trial compared pembrolizumab 
(flat dose of 200 mg every three weeks) with chemotherapy by investigators’ choice, including 
vinflunine and taxanes, in patients who recurred or progressed after a platinum-based regimen. A 
higher ORR was observed in patients treated with pembrolizumab (21.1% vs. 11.4% of the 
chemotherapy arm); moreover, an OS benefit was observed, regardless of PD-L1 expression (in the 
overall population 10.3 and 7.4 months, in the immunotherapy and chemotherapy arm, respectively, 
hazard ratio (HR) 0.73; 95% confidence interval (CI) 0.59 to 0.91; p = 0.002). Finally, pembrolizumab 
was associated with fewer grade 3–4 adverse events compared to vinflunine, paclitaxel, and 
docetaxel.  
Instead, the activity of atezolizumab was tested in the phase II IMvigor210 and the phase III 
IMvigor211 trials [39,40]. As stated above, the IMvigor210 trial was a 2-cohort phase II study aimed 
to evaluate the efficacy and safety of atezolizumab (1200 mg flat dose every three weeks) in 
untreated, cisplatin-ineligible patients (cohort 1) as well as in patients whose disease was refractory 
to platinum-based chemotherapy (cohort 2) [39]. In the cohort 2, including 315 eligible subjects, an 
ORR of 15% was observed, with a sustained response duration and an acceptable safety profile; 
moreover, in patients presenting PD-L1 expression ≥5% the ORR was higher (27%) and the survival 
benefit longer compared to the PD-L1 ≥ 1 and < 5% cohort and the PD-L1 < 1% group. On the basis of 
these promising findings, the role of atezolizumab was further assessed in the confirmatory phase 
III, open-label, randomized IMvigor211 trial [40], which compared atezolizumab to chemotherapy 
by investigators’ choice, including vinflunine and taxanes, in patients who recurred or progressed 
after a platinum-based regimen. The primary endpoint, OS in patients with PD-L1 expression ≥ 5%, 
did not significantly differ between the two arms, with a median OS of 11.1 and 10.6 months in 
atezolizumab and chemotherapy arms, respectively (HR 0.87; 95% CI 0.63–1.21; p = 0.41). Despite the 
negative primary endpoint, IMvigor211 provided useful data in terms of median duration of 
response, which was significantly higher in the ICI arm (15.9 vs. 8.3 months; HR 0.57; 95% CI 0.26–
1.26) and in terms of toxicity, with the PD-L1 inhibitor confirming a manageable safety profile. 
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Finally, the exploratory analysis of the intention to treat population showed a survival benefit for 
atezolizumab (HR 0.85; 95% CI 0.73–0.99).  
Nivolumab is a human monoclonal IgG4 antibody that blocks the human PD-1 receptor, whose 
efficacy in the post-platinum setting was explored in the CheckMate 275 trial [41]; in this phase II 
trial, nivolumab (240 mg flat dose every two weeks) showed an ORR of 20% with 2% CR in 270 
patients affected by advanced or metastatic UC. With regard to PD-L1 expression, ORR was 
significantly higher in the subgroup of patients with PD-L1 expression ≥5% (28.4%) compared to the 
PD-L1 ≥ 1% (23.8%) and the PD-L1 negative (16.1%) cohorts. 
A similar level of activity was observed with post-platinum avelumab and durvalumab in the 
multicohort phase Ib JAVELIN trial [42] and the single-arm, phase I/II Study 1108 [43], respectively. 
Avelumab (10 mg/kg every two weeks), an anti-PD-L1 antibody that blocks the binding of PD-L1 to 
PD-1, reported an ORR of 17% with 6% CR in platinum-refractory or cisplatin unfit patients; 
interestingly, in PD-L1 negative subgroup ORR fell to 9% while reached the 40% in PD-L1 ≥ 5% 
patients.  
Similarly, considering the cutoff of 25% of PD-L1 expression (assessed with 
immunohistochemistry (IHC) on tumor tissue via Ventana SP263 assay) in Study 1108, the subgroup 
of patients with PD-L1high achieved higher response rates and survival benefit compared to PD-L1low 
cohort (20 vs. 8 months) with the anti-PD-L1 human IgG1 durvalumab [43]. In Study 1108, patients 
were administered durvalumab intravenous infusion, 10 mg/kg every 2 weeks.  
Additional data from a number of ongoing prospective clinical trials will help to confirm the 
activity of ICIs in previously treated and untreated patients [44]; in the era of precision, tailor-made 
oncology, several questions are still unanswered, including the identification of predictive 
biomarkers, sequential treatment strategies, and proper selection of patients in advanced or 
metastatic UC. A non-negligible unanswered question is how to assess PD-L1 expression. For 
example, in KEYNOTE-052 and IMvigor210 PD-L1 cutoff was different and it was assessed 
differently; in KEYNOTE-052 PD-L1 positive tumors were those presenting a CPS ≥ 10% and PD-L1 
expression in formalin-fixed, paraffine-embedded tissue was determined using the PD-L1 clinical 
trial assay (PD-L1 IHC 22C3 pharmDx assay; Agilent Technologies, Carpinteria, CA, USA). 
Differently, in the IMvigor210 trial the VENTANA SP142 immunohistochemistry assay (Ventana 
Medical Systems, Inc.; Tucson, AZ, USA) was used to evaluate PD-L1 expression on 
tumor-infiltrating immune cells (IC) and a scoring criteria designated tumors as IC0, IC1, or IC2/3 
(PD-L1 expression on <1%, ≥1% and <5%, or ≥5% of IC, respectively). 
2.2. Target Therapies 
In the recent years, genomic characterization of advanced-stage UC has given an insight on 
which are molecular drivers at the basis of the oncogenesis and progression of UC and that could be 
potentially targetable (Figure 2) [45]. The Cancer Genome Atlas (TCGA) project for bladder cancer 
had the purpose to provide a comprehensive landscape of molecular alterations [46]. The first 
integrated analysis on 131 UC demonstrated statistically significant recurrent mutations in 32 genes. 
Furthermore, this analysis showed that 69% of the tumors presented potential therapeutic targets, of 
which 42% regarded the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin 
(mTOR) pathway and 44% in the receptor tyrosine kinase/MAPK pathway, and identified an 
in-frame activating FGFR3-TACC3 fusion in three tumors [46]. Alterations in the PI3K/AKT/mTOR 
pathway consisted in point mutations in PIK3CA (17%), mutation or deletion of TSC1 or TSC2 (9%), 
and overexpression of AKT3 (10%). Alterations in the receptor tyrosine kinase/RAS pathway 
included activation of FGFR3 (17%), amplification of EGFR (9%), mutations of ERBB3 (6%), and 
mutation or amplification of ERBB2 (9%). 
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Figure 2. Frequent potentially actionable mutations and pathways involved in UC. EGFR: epidermal 
growth factor receptor; ERK: mitogen-activated protein kinase; FGFR: fibroblast growth factor 
receptor; HER2: receptor tyrosine-protein kinase ERBB2; MAPK: mitogen-activated protein kinase; 
MEK: dual-specificity mitogen-activated protein kinase; mTOR: mammalian target of rapamycin; 
PDGFR: platelet-derived growth factor receptor; PI3K: phosphoinositide 3-kinase; PTEN: 
phosphatase and tensin homologue; VEGFR: vascular endothelial growth factor receptor. 
The TCGA expanded cohort analysis on 412 MIBC that identified 58 significantly mutated 
genes and confirmed the high mutation rate of MIBC [47]. Moreover, RNA expression analysis 
identified five expression subtypes that may stratify response to different treatments: 
luminal-papillary (35%), luminal (6%), basal-squamous (35%), luminal-infiltrated (19%), and 
neuronal (5%) [47]. Recently, a consensus molecular classification of MIBC has been proposed on the 
basis of 1750 MIBC transcriptomic profiles from 18 datasets comparing six molecular classification 
schemes. Six molecular classes were identified: luminal papillary, luminal nonspecified, luminal 
unstable, stroma-rich, basal/squamous, and neuroendocrine-like [48]. This consensus classification 
has possible therapeutic implications. In fact, the different consensus classes are associated with 
different stromal components and genetic alteration that could possibly identify a subset of patients 
more likely to respond to immunotherapy or to target therapy. The identification of molecular 
alterations is of great importance since many target therapies are being studied for the management 
of advanced UT [49]. 
FGFR1, FGFR2, FGFR3, FGFR4 are tyrosine kinases receptor that have been found altered in UC 
[50]. Activating FGFR3 mutations are most common in NMIBC, being identified in approximately 
two-third of these early stage tumors, while their frequency in MIBC is lower (less than 25%), 
including amplifications, mutations, and fusions in FGFR gene [51–54]. The activating FGFR3 
mutation leads to ligand-independent receptor dimerization and constitutive downstream signal 
transduction [54]. The presence of activating point mutations in FGFR3 in early stage tumors is 
associated with favorable outcome [55]. Approximately 7% of UC present an amplification of FGFR1 
[56]. FGFR1 has two splicing variants, FGFR1α and FGFR1β, that are equally expressed in normal 
urothelium, but the FGFR1β variant is predominant in UC and its expression correlates with tumor 
grade and stage [57]. The luminal-papillary subtype of the consensus classification is characterized 
by a high rate of FGFR3 mutations and translocations, suggesting that these tumors may respond to 
FGFR inhibitors [48]. Moreover, FGFR3 pathway was found to be activated in non-T-cell-inflamed 
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tumors that are likely to present intrinsic resistance to ICIs [58]. Furthermore, immunotherapy seems 
to be less effective on TCGA luminal I subtype also based on an exploratory analysis of a phase 2 
trial: luminal I cluster presented lower expression levels of CD8+ genes, lower PD-L1 immune cell or 
tumor cell expression, and lower responses to the anti-PD-L1 atezolizumab [39]. 
With these premises, multi-tyrosine kinase inhibitors targeting FGFR alterations have been 
studied in patients with metastatic UC [59]. The results of a phase 2 trial (BLC2001) testing the 
tyrosine kinase inhibitor of FGFR1–4 erdafitinib have been recently published [60]. In this trial, 99 
patients with locally advanced or metastatic UC with FGFR3 mutation or FGFR2/3 fusion and 
progressed to at least one previous chemotherapy or treatment naïve if cisplatin ineligible were 
assigned to receive erdafitinib, 8 mg per day in a continuous regimen. The primary endpoint of the 
study was ORR. The treatment was found to be active with an ORR of 40% (3% with a complete 
response and 37% with a partial response). The median duration of progression-free survival (PFS) 
was 5.5 months and the median duration of OS was 13.8 months. Interestingly, the 22 patients 
previously treated with ICIs presented a response rate of 59%. Grade 3 or higher treatment-related 
adverse events were reported in nearly half the patients and the most common of any grade were 
hyperphosphatemia, stomatitis, diarrhea. FDA granted accelerated approval to erdafitinib for 
patients with FGFR3 or FGFR2 genetic alterations progressed during or following 
platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant 
platinum-containing chemotherapy. 
Another pathway implicated in UC pathogenesis and progression is vascular endothelial 
growth factor receptors (VEGFR) 1 and 2 and their ligands (vascular endothelial growth factor, 
VEGF-A, -B, -C, and -D) [61,62]. Angiogenesis by microvessel quantification resulted to be an 
independent predictor of survival in patients with invasive bladder cancer and serum levels of 
VEGF have been correlated with tumor stage and grade, vascular invasion and presence of 
metastases [63–65]. 
VEGF/VEGFR inhibitors as single agents or in combination with chemotherapy have been 
investigated for the treatment of advanced UC. Single agent treatment with sorafenib, pazopanib, 
cabozantinib and sunitinib resulted to have limited activity and limited effect on clinical outcomes 
[66–69]. Similarly, combination therapies failed to be shown to be more active than chemotherapy 
alone: vandetanib combined with docetaxel or sunitinib associated with gemcitabine and cisplatin 
did not improve clinical activity and were more toxic [70,71].  
The monoclonal antibody against VEGF Bevacizumab was evaluated in a phase II trial in 
association with gemcitabine and cisplatin in first line of therapy for metastatic UC: the combination 
treatment showed an ORR of 72% and an OS of 19.1 months [72]. Unfortunately, the subsequent 
phase III trial (CALGB-90601 Alliance) failed to show an advantage in OS, the primary endpoint of 
the study, for the combination regimen [73]. 
A phase III randomized trial investigated the combination of ramucirumab plus docetaxel 
versus placebo plus docetaxel in 530 patients with advanced or metastatic UC progressed during or 
after platinum-based chemotherapy [74]. The experimental arm was associated with a significantly 
longer PFS (4.07 months versus 2.76 months in the docetaxel-alone arm) with no OS benefit. 
Additional follow-up confirmed the advantage in PFS (4.1 months versus 2.8 months in the 
experimental arm versus the control arm, respectively; HR 0.696; p = 0.0002) and the lack of 
statistically significant advantage in OS for the combination treatment (9.4 months in the 
experimental arm versus 7.9 months in the placebo group; stratified HR 0.887; p = 0.25) [75]. 
2.3. Antibody-Drug Conjugates  
Another interesting emerging class for the treatment for metastatic UC is antibody-drug 
conjugate (ADC), that consists in monoclonal antibody against a target expressed on cancer cell 
bounded to a cytotoxic agent with a protease-cleavable or non-cleavable linker [76]. When the 
monoclonal antibody binds to a tumor antigen, the drug is internalized and the active 
chemotherapeutic agent is released into the selected cells, leading to cell death. This mechanism of 
cell-killing is supposed to limit exposure and toxicity of cytotoxic agents. One of the most promising 
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antibody-drug conjugate currently under investigation in metastatic UC is enfortumab vedotin 
(ASG-22ME). This ADC is composed of an anti nectin-4 (a cell adhesion molecule highly expressed 
in UC) monoclonal antibody liked to a micro-tubule-disrupting agent (monomethyl auristatin E). 
The phase 1 EV-101 trial evaluated enfortumab vedotin in patients with Nectin-4-expressing solid 
tumors, including 155 heavily pretreated patients with metastatic UC [77]. Single-agent enfortumab 
vedotin resulted to be well tolerated and showed clinically meaningful and durable responses with 
an ORR of 43%, a duration of response of 7.4 months, a median OS of 12.3 months, and OS rate at 1 
year of 51.8%.  
The phase II EV-201 single-arm study investigated enfortumab vedotin in locally advanced or 
metastatic UC patients previously treated with ICI and platinum-containing chemotherapy (Cohort 
1) or an ICI and no prior chemotherapy (Cohort 2) [78]. The preliminary data of cohort 1 enrolling 
128 patients have been presented and showed an ORR of 42% with 9% complete responses. The 
safety profile was manageable with fatigue (50%), alopecia (48%), and decreased appetite (41%) as 
most common treatment-related adverse events. Of note, one death was reported as treatment 
related by the investigator (interstitial lung disease). Based on these results, the FDA granted 
accelerated approval to enfortumab vedotin for patients with locally advanced or metastatic 
urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and a platinum-containing 
chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. A phase III trial 
evaluating enfortumab vedotin in patients progressed to previous ICI and platinum containing 
chemotherapy is ongoing (NCT03474107, EV-301). 
Preliminary data for the combination of enfortumab vedotin with pembrolizumab for first line 
treatment of cisplatinum ineligible patients with metastatic UC are encouraging. The phase Ib study 
EV-103 (NCT03288545) demonstrated the efficacy of this combination approach in this subset of 
patients with a tolerable and manageable safety profile [79,80]. At the recent 2020 American Society 
of Clinical Oncology (ASCO) Genitourinary Cancer Symposium, the updated results were presented 
by Rosenberg: at a median follow-up of 11.5 months, investigator-assessed objective response rate 
was confirmed to be 73.3%, with 15.6% complete responses [81]. The most common adverse events 
were fatigue (58%), alopecia (53%), and neuropathy (53%). A phase III trial with this combination 
therapy is ongoing (NCT04223856, EV-302). 
Another ADC that has been evaluated in metastatic UC is Sacituzumab govitecan, a humanized 
anti-Trop-2 (an epithelial cell surface antigen overexpressed in UC) monoclonal antibody linked 
with SN-38 (the active metabolite of irinotecan). Sacituzumab govitecan has been investigated in a 
phase I/II basket study in 45 patients progressed after at least one prior systemic therapy [82]. The 
ORR was 31%, including 2 CR and 12 PR. In patients with visceral involvement the ORR was 27% 
and in patients previously treated with ICIs it was 23%. Median PFS and OS were 7.3 months and 
18.9 months, respectively. Among grade ≥3 adverse events there were neutropenia/neutrophil count 
decreased (38%), anemia (11%), hypophosphatemia (11%), diarrhea (9%), fatigue (9%), and febrile 
neutropenia (7%). A global, single-arm, phase II trial which is ongoing (TROPHY-U-01, 
NCT03547973) is evaluating the antitumor activity of Sacituzumab govitecan (10 mg/kg, days 1 and 
8 of 21-day cycles) in patients with advanced UC. Cohort 1 [83] assessed the activity in 35 patients 
progressed to platinum-based regimens and ICIs while cohort 2 [84] enrolled 18 platinum-ineligible 
patients who progressed after first-line ICI. The interim results of cohort 1 demonstrated an ORR of 
29% with 2 confirmed CR, 5 confirmed PR, and 3 unconfirmed PR. The preliminary results of cohort 
2 showed an ORR of 28% with 4 confirmed PRs, and 1 PR pending confirmation. The safety profile 
was consistent with prior reports in both cohorts no treatment-related deaths were reported. 
The evolution of practice changing treatments, including promising therapies approved by 
FDA, for metastatic UC is depicted in Figure 3. Current treatment scenario in metastatic UC is 
reported in Figure 4. 
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Figure 3. Evolution of practice changing treatments for metastatic urothelial carcinoma. For many 
years, platinum-based chemotherapy has been the gold standard treatment for patients with 
metastatic urothelial carcinoma. Since 2017, immune checkpoint inhibitors entered in the treatment 
scenario. In 2019, two new treatment strategies showed promising results and have been granted 
accelerated approval by the US Food and Drug Administration: erdafitinib and enfortumab vedotin. 
 
Figure 4. Current treatment algorithm for metastatic urothelial carcinoma. Based on cisplatin 
eligibility and PD-L1 positivity, patients are currently being treated as indicated in the figure. If 
cisplatin eligible (depending on eGFR, ECOG PS, peripheral neuropathy, audiometric hearing loss) 
patients should be treated with cisplatin-based chemotherapy. In cisplatin ineligible patients, the 
treatment changes according to PD-L1 positivity. If PD-L1 negative, patients should be treated with 
carboplatin-based chemotherapy. If PD-L1 positive, carboplatin-based chemotherapy or 
immunotherapy are the available options. Second and later lines of treatment depend on previous 
exposure to chemotherapy or immunotherapy. Enrollment in clinical trials should always be 
considered as a treatment option. CHT: chemotherapy. ICI: immune checkpoint inhibitor. PD: 
progressive disease. FGFR: fibroblast growth factor receptor. CPS: combined positive score. PD-L1: 
programmed death ligand-1. eGFR: estimated glomerular filtration rate. ECOG PS: eastern 
cooperative oncology group performance status. 
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3. Therapeutic Approaches UNDER Evaluation 
3.1. Ongoing Trials Evaluating ICIS 
3.1.1. Combination of ICIs with Cytotoxic Chemotherapy 
Several trials exploring the role of ICIs plus chemotherapy in different settings and 
combinations are currently ongoing. As regards the first-line setting, the randomized phase III 
KEYNOTE-361 trial (NCT02853305) is investigating the safety and efficacy of front-line 
pembrolizumab with or without chemotherapy (GC in eligible patients or gemcitabine–carboplatin 
combination in cisplatin unfit subjects) [85]. OS and PFS are the primary endpoints of this study, 
with ORR and safety assessed as secondary endpoints. Similarly, the phase III IMvigor130 trial 
(NCT02807636) has enrolled previously untreated patients affected by advanced or metastatic UC in 
a 1:1:1 ratio to either atezolizumab plus platinum-gemcitabine, atezolizumab monotherapy, or 
platinum-gemcitabine plus placebo [86]. The primary endpoints are OS and PFS; secondary 
endpoints are safety, ORR and DCR. As previously stated, preliminary findings of these two trials 
showing a close relation between PD-L1 expression, type of treatment and clinical outcomes have 
had a relevant impact on current indications of pembrolizumab and atezolizumab in UC. More 
specifically, FDA revised previous indications for the two ICIs, which are now limited for (1) 
first-line treatment in cisplatin-ineligible patients whose tumors express PD-L1 (CPS ≥ 10% for 
pembrolizumab and PD-L1 stained tumor-infiltrating immune cells covering ≥ 5% of the tumor area 
in the case of atezolizumab), (2) subjects which have disease progression during or following 
platinum-containing chemotherapy, or (3) patients unfit for any platinum-based chemotherapy, 
regardless of PD-L1 expression. 
The anti-PD-L1 agent atezolizumab is being also investigated in a phase II trial (NCT03093922) 
aimed to evaluate the safety and efficacy of two different dosing schedules of atezolizumab in 
combination with GC as front-line treatment for advanced or metastatic UC. Regarding less 
commonly used ICIs, a randomized, placebo-controlled, phase III trial (NCT03967977) has been 
initiated to investigate the safety and efficacy of front-line tislelizumab plus standard chemotherapy 
(gemcitabine plus either cisplatin or carboplatin) versus placebo plus standard chemotherapy 
(gemcitabine plus either cisplatin or carboplatin). Tislelizumab (BGB-A317) is a humanized 
monoclonal PD-1 antibody which is being evaluating in several solid tumors [87].  
With regard to second-line setting, atezolizumab is currently under evaluation in 
cisplatin-ineligible patients in an ongoing phase II trial (NCT03737123). In this study, subjects who 
previously received sequential or concurrent ICI and carboplatin-based chemotherapy will be 
treated with atezolizumab plus docetaxel combination; conversely, patients who have already 
received an ICI without prior platinum-based chemotherapy will be treated with atezolizumab plus 
carboplatin-gemcitabine.  
Another anti-PD-L1 agent, avelumab, is being investigated in phase II trial on previously 
untreated, cisplatin-ineligible patients (NCT03390595). In this study, patients are randomized in a 
1:1 ratio to receive avelumab in combination with carboplatin-gemcitabine chemotherapy versus 
carboplatin-gemcitabine alone. Avelumab is also under investigation in a phase II trial comparing 
avelumab plus GC versus GC in cisplatin fit, treatment naïve patients (NCT03324282). PT-112, a 
platinum-based agent belonging to the phosphaplatin family, is under evaluation in combination 
with avelumab in the ongoing phase I/II PAVE-1 trial (NCT03409458).  
The combination of the anti-PD-1 antibody pembrolizumab with paclitaxel is currently under 
investigation in a phase II trial (NCT02581982) on platinum-refractory patients. Lastly, several other 
combinations of anti-PD-1/PD-L1 agents with cytotoxic agents such as pemetrexed, platinum, and 
etoposide are being evaluated in a series of ongoing trials (NCT03744793; NCT03582475). 
Ongoing phase I/I/II trials, either recruiting or active not recruiting, of ICIs in combinations 
with cytotoxic chemotherapy in advanced or metastatic UC are summarized in Table 1.
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Table 1. Ongoing phase I/II/III trials of immune checkpoint inhibitors in combination with cytotoxic chemotherapy. ORR: overall response rate. PFS: 
progression-free survival. OS: overall survival. 
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3.1.2. Combination of ICIs with Other ICIs 
In recent years, checkpoint-inhibition combination therapies have provided outstanding 
efficacy gains in several malignancies including melanoma, lung cancer and renal cell carcinoma 
[88,89]. The underlying rationale for these combinations lies in the synergistic effect provided by the 
inhibition of CTLA-4 and PD-1/PD-L1, resulting in an enhance of T-cell function through distinct 
pathways [90]. The results obtained in a number of cancer types have led to the recent attempt to 
translate these experiences in advanced or metastatic UC. 
The phase 1/2 CheckMate-032 trial investigated ipilimumab plus nivolumab versus nivolumab 
alone in several malignancies, including platinum-refractory patients affected by advanced or 
metastatic UC [91,92]. In this cohort of subjects, the combination of the two immunotherapies 
yielded a promising response rate of 38%; moreover, subjects treated with the combination showed a 
median OS of 15.3 months versus 9.9 months in the nivolumab arm. The combination of an anti-PD-1 
and a CTLA-4 antibody is being investigated also in the CheckMate-901 trial (NCT03036098) [93], 
aimed to evaluate the efficacy of nivolumab ± ipilimumab versus GC or carboplatin-gemcitabine 
chemotherapy. The same combination with modified schedules and additional 
nivolumab/ipilimumab “boost” cycles is under evaluation also in a Phase II trial (NCT03219775, 
TITAN-TCC) on treatment naïve and platinum-refractory patients with advanced or metastatic UC. 
The anti-PD-L1 agent durvalumab, registered by FDA as monotherapy in previously treated 
patients affected by advanced or metastatic UC, is currently under investigation in combination with 
the CTLA-4 IgG2-kappa monoclonal antibody tremelimumab in the DANUBE (NCT02516241) and 
the NILE (NCT03682068) trials [94,95]. The DANUBE is an ongoing randomized, open-label, phase 
III trial aimed at ascertaining the value of front-line durvalumab ± tremelimumab versus 
platinum-gemcitabine chemotherapy in advanced or metastatic UC [90]. In the same setting of 
previously untreated patients, the NILE trial randomized subjects to three different cohorts: 
durvalumab plus tremelimumab plus platinum-gemcitabine; durvalumab plus 
platinum-gemcitabine; platinum-gemcitabine [95].  
Ongoing phase II/III trials, either recruiting or active not recruiting, of ICIs in combinations 
with other ICIs in advanced or metastatic UC are summarized in Table 2.
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3.1.3. Combination of ICIs with Antiangiogenic Agents 
Given the importance of angiogenesis as a crucial process in the carcinogenesis and progression 
of UC, ICIs are under evaluation also in combination with VEGFR antibodies and TKIs, including 
bevacizumab, ramucirumab, lenvatinib, and several others [96,97].  
As regards front-line treatment, the VEGF-A monoclonal antibody bevacizumab is being 
investigated in a phase II trial assessing bevacizumab plus atezolizumab in treatment-naïve, 
cisplatin-ineligible patients (NCT03272217).  
Axitinib, a highly selective VEGFR-1, -2, and -3 inhibitor, is currently under investigation as 
front-line treatment in combination with avelumab in the ongoing phase II trial JAVELIN Medley 
VEGF (NCT03472560). Enrolled subjects are deemed ineligible for receiving cisplatin-containing 
first-line chemotherapy and the primary endpoint is ORR, defined as a confirmed CR or PR.  
Ramucirumab is an IgG1 monoclonal antibody that binds VEGFR-2 preventing ligand binding 
and receptor-mediated pathway activation in endothelial cells [98]. An ongoing, phase I trial is 
assessing the safety of ramucirumab in combination with pembrolizumab in previously treated 
patients affected by a number of solid cancers, including UC (NCT02443324).  
Lenvatinib is a small TKI able to inhibit VEGFR-1, FGFR1–4, stem cell factor receptor (KIT), 
platelet-derived growth factor receptor α (PDGFRα), and rearranged during transfection (RET) [99]. 
The combination of lenvatinib and pembrolizumab is being investigated as front-line treatment in 
the phase III LEAP-011 trial (NCT03898180) which is evaluating the combination in cisplatin-unfit 
subjects with PD-L1 CPS ≥10 or in patients deemed ineligible for any platinum-based regimen, 
regardless of PD-L1 expression.  
Cabozantinib is another small TKI inhibiting a plethora of targets which play an important role 
in tumor growth, angiogenesis, and survival, such as VEGFR-2, MET, RET, KIT, AXL, and FLT3 
[100,101]. Following the findings of a recent phase I trial where cabozantinib plus nivolumab plus 
ipilimumab yielded an ORR of 36% across all genitourinary cancers [102], this molecule is being 
evaluated in combination with pembrolizumab (NCT03534804), durvalumab (NCT03824691), 
atezolizumab (NCT03170960), and nivolumab plus ipilimumab (NCT03866382) in treatment-naïve 
and previously treated patients. Moreover, cabozantinib is also under investigation in a phase II trial 
(NCT04066595) which is enrolling previously treated subjects with platinum-based chemotherapy 
(cohort 1) and platinum-based chemotherapy plus ICIs (cohort 2). 
The anti-VEGF recombinant EphB4-HSA fusion protein is currently under evaluation in 
combination with pembrolizumab in an ongoing phase II trial (NCT02717156). The study is enrolling 
treatment naïve patients affected by locally advanced or metastatic UC.  
Apatinib, a small-molecule TKI which selectively inhibits VEGFR-2 resulting in a decrease in 
endothelial proliferation, migration, and tumor microvascular density, is under evaluation in 
combination with pembrolizumab in a phase I/IIa trial (NCT03407976; APPEASE). In this study, 
eligible subjects must have progressed during or following platinum-based chemotherapy.  
Lastly, sitravatinib, a small TKI able to inhibit VEGFR, PDGFR, KIT, RET, and MET [103], is 
currently under investigation in combination with nivolumab in a non-randomized, Phase II trial 
(NCT03606174). Although all patients are planned to receive the same treatment (nivolumab 240 mg 
every 2 weeks or 480 mg every 4 weeks plus sitravatinib 120 mg orally once per day continuously in 
28-day cycles), eligible subjects are assigned to eight different cohorts, based upon previous 
therapies for UC. 
Ongoing phase I/II/III trials, either recruiting or active not recruiting, of ICIs in combinations 
with antiangiogenic agents in advanced or metastatic UC are summarized in Table 3.
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Table 3. Ongoing phase I/I/II trials of combinations between immune checkpoint inhibitors with antiangiogenic agents. ORR: overall response rate. PFS: 
progression-free survival. OS: overall survival. 
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3.1.4. ICI Monotherapy 
Although combination therapies are displaying the ability to broaden the anticancer activity of 
ICIs and the majority of ongoing trials are testing ICIs in combination with other anticancer agents, 
some trials are evaluating the role of monotherapy in different settings.  
The anti-PD-1 agent pembrolizumab is being evaluated in a randomized, double-blinded phase 
II trial (NCT02500121) assessing the role of maintenance pembrolizumab (200 mg flat dose every 
three weeks, for up to 24 months) versus placebo after front-line chemotherapy in patients affected 
by metastatic UC. Eligible subjects must have achieved CR, PR or stable disease (SD) after 4 to 6 
cycles of first-line platinum-based chemotherapy; six-month PFS assessment, regardless of PD-L1 
expression, is the primary outcome. Maintenance treatment with ICIs is also under investigation in 
an ongoing phase III trial (NCT02603432) comparing avelumab maintenance plus best supportive 
care versus best supportive care alone in patients whose disease did not progress after first-line 
platinum-based chemotherapy.  
Atezolizumab treatment is being tested in the real-world phase III SAUL trial (NCT02928406) 
and preliminary results of this study assessing the role of atezolizumab in a pretreated population of 
1004 UCs have been recently published [104]. Median OS and PFS were 8.7 and 2.2 months 
respectively, with an ORR of 13%. The trial enrolled patients who experienced progression during or 
after one to three prior therapies, of which 10% had ECOG-PS 2 and 98% were platinum pretreated.  
Toripalimab (JS001), a recombinant, humanized PD-1 monoclonal antibody capable of 
preventing the binding of PD-1 with PD-L1 and PD-L2, is being evaluated as monotherapy in 
pretreated advanced or metastatic UC in an ongoing phase II trial (NCT03113266). The primary 
outcome is ORR, with duration of response, PFS, OS, and safety as secondary outcomes.  
The anti-CTLA-4 agent tremelimumab is currently being evaluated as monotherapy in a phase 
II trial (NCT03557918) assessing ORR in patients with metastatic UC which previously received 
PD-1/PD-L1 blockade.  
The novel anti-PD-L1 CK-301 (Cosibelimab) is being tested in a phase I trial (NCT03212404) on 
a number of advanced malignancies, including UC. Lastly, a phase I trial (NCT03053466) is studying 
the role of the anti-PD-1 agent APL-501 in patients affected by advanced solid tumors presenting at 
least 1% of PD-L1 expression by IHC. 
Ongoing phase I/II/III trials, either recruiting or active not recruiting, of ICI monotherapy in 
advanced or metastatic UC are summarized in Table 4.
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3.1.5. Novel Immunotherapy Approaches 
With the aim to enhance the response to ICIs and other anticancer agents, a number of novel 
immunomodulatory molecules and brand-new combinations are being evaluated in UC [105,106].  
A recently emerging immunotherapeutic target is represented by the indoleamine 
2,3-dioxygenase-1 (IDO1), an enzyme playing a crucial role in immunosuppression, angiogenesis, 
and metastasis [107]; in fact, IDO1 is an immune regulatory enzyme which promotes tryptophan 
depletion, a mechanism necessary for T-cell survival [108]. More specifically, IDO1 enhances the 
activity of CD4+ T regulatory cells and myeloid-derived suppressor cells and, conversely, is able to 
suppress CD8+ T effector and natural killer (NK) cells [109]. Despite early promising results, the 
combination of pembrolizumab plus the IDO-1 inhibitor epacadostat came up short against its 
primary endpoints of OS and PFS; thus, the two trials assessing the role of the anti-IDO-1 ± 
pembrolizumab in treatment-naïve, cisplatin ineligible subjects (NCT03361865) and in 
platinum-refractory patients (NCT03374488) arrested recruitment. Currently, the safety of the 
combination of pembrolizumab plus KHK2455, a long-active selective IDO-1 inhibitor, is being 
evaluated in an ongoing Phase I study on platinum-refractory patients affected by metastatic UC 
(NCT03915405). 
Another attracting target is represented by the tumor necrosis factor receptor OX40 (CD134) 
[110,111]; when activated by its ligand OX40L, OX40 is involved in T-cell signaling activation, 
promoting T-cell survival and enhancing the expression of several molecules such as Bcl-2 
anti-apoptotic molecules, cytokines, cyclin A, and cytokine receptor [112]. Therefore, as OX40 may 
promote proliferation and survival of CD4+ and CD8+ T cells, immunostimulatory agonistic agents 
are currently under investigation in several solid malignancies [113]. The OX40 agonist PF-04518600 
is being evaluated as monotherapy or in combination with the cytokine modulator utomilumab 
(PF-05082566)—a monoclonal antibody with agonist activity toward 4-1BB (CD137), a receptor 
expressed on NK, CD8+, and CD4+ T cells [114]. Preliminary results of this trial, which includes also 
a cohort of patients affected by UC, have shown an ORR of 5.4% across all cancer types; nevertheless, 
the promising 50% of ORR reported in the UC subgroup has led to the NCT03217747 and the Javelin 
Medley (NCT02554812) ongoing phase I/II trials which are evaluating the OX40 agonist PF-04518600 
in combination with ICIs, radiation therapy, utomilumab, and cytotoxic chemotherapy. Finally, the 
hexavalent OX40 agonist INBRX-106 is currently under investigation as monotherapy or in 
combination with pembrolizumab for previously treated patients in a phase I trial (NCT04198766). 
Other immunotherapeutic strategies currently under investigation include cytokine agonists 
such as NKTR-214 (bempegaldesleukin)—an IL-2 pathway agonist which targets CD122, a protein 
expressed in NK and CD8 T cells—ALT-803 and YT107 [115,116]. Following promising early results 
from a Phase I trial across several solid tumors (NCT02983045, PIVOT-02), NKTR-214 is currently 
being evaluated in combination with nivolumab in treatment-naïve, cisplatin ineligible patients 
affected by locally advanced or metastatic UC (NCT03785925, PIVOT-10). Conversely, NKTR-214 is 
now being investigated in the phase I PROPEL trial (NCT03138889) assessing the combination of 
atezolizumab plus NKTR-214 in platinum-refractory UC. Similarly, the recombinant human 
interleukin-7 CYT-107 is under evaluation in combination with atezolizumab versus atezolizumab 
alone in platinum-refractory UCs (NCT03513952); the IL-15 superagonist ALT-803 is being 
investigated as combination therapy with pembrolizumab, nivolumab, atezolizumab, or avelumab 
in previously treated patients (NCT03228667). Finally, an ongoing open-label, non-randomized 
phase I study (NCT03809624) is testing the role of INBRX-105 in advanced solid tumors. INBRX-105, 
a next generation bispecific antibody targeting PD-L1 and 4-1BB, blocks inhibitory PD-1/PD-L1 axis 
and simultaneously activates essential co-stimulatory activity via 4-1BB. Other bispecific antibodies 
such as GEN1046, XmAb20717, XmAb22841, and XmAb23104 are currently under investigation in 
ongoing phase I (NCT03752398, NCT03849469, NCT03517488) and phase I/II (NCT03917381) trials. 
Another potential target is lymphocyte activation gene-3 (LAG-3, CD223), a co-inhibitory 
receptor able to suppress T-cell activation and cytokines secretion [117]; more specifically, LAG-3 
overexpression in tumor cells is involved in the phenomenon of immune exhaustion, with 
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suppression of T-cell function [118,119]. Thus, LAG-3 inhibitors as monotherapy or in combination 
with anti-PD-1 agents are currently being explored in several phase I and II trials in advanced 
malignancies, including pretreated UC (NCT03538028, NCT03250832). 
T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) is another co-inhibitory 
receptor expressed on regulatory T cells, effective T cells, tumor cells, and innate immune cells 
(macrophage and dendritic cells) [120]. TIM-3 expression has been recently associated with poor 
prognosis in a number of cancer types, including UC [121–123]; because of the implication of TIM-3 
overexpression in T-cell dysfunction and exhaustion, several TIM-3 inhibitors are currently being 
studied in advanced cancer. Among them, INCAGN02390 is under evaluation in a phase I trial 
(NCT03652077) assessing its role as monotherapy in previously treated metastatic malignancies 
including UC.  
Glucocorticoid-induced TNF receptor family related receptor (GITR) represents a 
co-stimulatory receptor that binds the GITR ligand (GITRL) [124]; the activation of GITR can result 
in signals influencing the activity of CD4+, CD8+ and regulatory T cells, playing an important role in 
autoimmune and inflammatory diseases as well as in anticancer immune response [125,126]. Thus, 
GITR seems to be a promising target for novel immunotherapy agents. A phase I/II trial analyzing 
the combination of nivolumab, ipilimumab, and the GITR agonist INCAGN01876 (NCT03126110) in 
patients with metastatic malignancies including UC is recruiting at present.  
Chimeric antigen receptor (CAR)-T immunotherapy has shown impressive responses in a 
number of B cell malignancies and is currently being tested in several solid tumors, including 
advanced or metastatic UC (NCT03185468) [127]. CAR-T action is based on engineered T cells 
expressing a CAR; current second-generation CAR are receptors composed of (1) an extracellular, 
epitope-specific binding domain, (2) a transmembrane domain, (3) and an intracellular domain of 
the T cell receptor; this last domain consists in its turn of costimulatory molecules such as CD28, 
4-1BB, and the CD3ζ chain, and is involved in a massive activation of T cells which is independent 
from T-cell receptor (TCR)—major histocompatibility complex (MHC) interactions [128,129]. 
Lastly, another promising immunotherapeutic strategy lies in tumor vaccines (TVs), which are 
currently under investigation in many solid tumors [130,131]. As regards UC, the majority of 
developing TVs concerns BCG-relapsing, non-muscle invasive disease, where neo-antigens are 
being studied in combination with immune-stimulating adjuvant agents, cytotoxic agents, and/or 
mTOR inhibitors (NCT01353222, NCT02015104, NCT01498172). Cancer vaccines are also under 
investigation in combination with ICIs, as in the case of the NCT03689192 and the NCT03639714 
trial. In the NCT03639714 Phase 1/2 Study, two vaccines vectors (GRT-C901 and GRT-R902)—used 
as immune boosts—are being investigated in combination with nivolumab plus ipilimumab in 
patients affected by a number of solid cancers including previously treated, metastatic UC. 
Ongoing phase I/II/III trials, either recruiting or active not recruiting, of novel immunotherapy 
approaches in advanced or metastatic UC are summarized in Table 5.
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3.2. PARP Inhibitors 
One of the new promising therapeutic approaches is the use of Poly(ADP-ribose) polymerase 
(PARP) inhibitors that target DNA repair gene mutations and have been proven active in other type 
of cancer like ovarian, breast, and prostate cancer [132,133]. 
Regarding UC, genomic alterations in DNA repair genes like ATM, ERCC2, RAD51B were 
found in 2–14% and in BRCA 1/2, PALB2, FANCD2, ERCC2, ATM in 3.7–12.3% of MIBC [47,134]. 
Moreover, patients with DNA damage response and repair (DDR) gene alterations treated with 
platinum based chemotherapy resulted to have better PFS and OS [135]. In fact, in multiple tumors 
the presence of DDR gene aberrations correlates with an enhanced sensibility to platinum 
compounds [136]. Based on these results, PARP inhibitors have been studied in UC as well [137–
140]. At the recent ASCO Genitourinary Cancers Symposium 2020, the results of the study ATLAS 
(NCT03397394) were presented [136]. This phase II trial assessed the efficacy and safety of the PARP 
inhibitor rucaparib in 97 patients with locally advanced or metastatic UC with or without 
homologous recombination deficiency (HRD), progressed to one or two prior treatments. Total of 
20.6% of patients were HRD-positive, 30.9% were HRD-negative, and 48.5% had unknown HRD 
status. Among patients with sequencing results (64 patients), deleterious alterations in BRCA1, 
BRCA2, RAD51C, PALB2 were infrequent (9.4%). Common alterations were found in TP53 (52.4%) 
and in FGF/FGFR pathway (77.6%). The results showed that there were no confirmed responses to 
rucaparib, 28.1% of patients achieved a stable disease as best response with no difference in efficacy 
between HRD-negative and HRD-positive patients. The trial was discontinued because 
protocol-defined continuance criteria were not meet. Two phase II trials are investigating the PARP 
inhibitor olaparib in monotherapy in chemotherapy naïve cisplatin ineligible patients or progressed 
to first line treatment selected for DDR mutations (NCT03448718) and in patients with DNA-repair 
defects progressed to 1 or 2 prior treatment regimens (NCT03375307). 
A phase II trial is currently investigating the PARP inhibitor niraparib as maintenance therapy 
until disease progression or unacceptable toxicity or death in patients unselected for DDR 
mutational status not progressing to first line platinum-based chemotherapy (NCT03945084). 
Another strategy being tested is combination therapy of PARP inhibitors with ICIs or target 
therapies. 
Indeed, the presence of alteration in DDR genes has been associated with higher mutational 
load and higher response to ICIs in patients with UC [141,142]. Based on these observations, several 
combinations of PARP inhibitors and PD-1/PD-L1 inhibitors are currently being tested: durvalumab 
plus olaparib (module B, NCT02546661, active not recruiting; NCT03459846, active not recruiting), 
rucaparib plus nivolumab (NCT03824704, active not recruiting), niraparib plus atezolizumab 
(NCT03869190, recruiting). 
The phase I BISCAY (NCT02546661) trial is evaluating the combination of durvalumab with 
olaparib or a FGFR1-3 inhibitor (AZD4547) or a TORC 1 and 2 inhibitor (vistusertib) in platinum 
refractory, immuno-therapy naïve UC patients allocated depending on tumour DNA alterations 
determined by next generation sequencing. Total of 391 patients were screened and NGS analysis 
showed the following absolute frequency of biomarkers: FGFR1–3 fusions or FGFR3 activating 
mutations in 21% of cases (83 patients in the AZD4547 arm/391), HRR deleterious gene alterations 
(ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCI, FANCL, PALB2, RAD51B, 
RAD51C, RAD51D, RAD54L) in 14% of cases (54 patients in the olaparib arm/391), RICTOR 
amplification and TSC1/TSC2 loss or inactivating mutations in 15% cases (60 patients in the 
Vistusertib arm/391). The preliminary results available on 14 patients with homologous 
recombination repair genomic alterations treated with olaparib and durvalumab showed a high 
tumor mutation burden and a confirmed ORR of 35.7%, a 6-months PFS rate of 42%, 1-years OS rate 
of 54% [143]. 
A phase Ib-II trial (NCT03992131) is evaluating the combination between the PARP inhibitor 
rucaparib and lucitanib, a VEGFR1-2-3, FGFR1-2, and PDGFRα-β inhibitor, or sacituzumab 
govitecan. 
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Ongoing phase I/II/III trials, either recruiting or active not recruiting, of PARP inhibitors in 
advanced or metastatic UC are summarized in Table 6.
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Table 6. Ongoing phase I/II/III trials of PARP inhibitors. ORR: overall response rate. PFS: progression-free survival. OS: overall survival. 
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3.3. Target Therapy 
As already discussed, the FGFR inhibitor erdafitinib is a promising treatment strategy in 
patients with FGF/FGFR alterations. In these subgroup of patients, other therapies directed at 
inhibiting FGFR are currently being tested: PRN1371, a FGFR 1-4 inhibitor, in a phase I trial in 
previously treated patients (NCT02608125); Pemigatinib, a FGFR1-3 inhibitor, in phase II trial in 
patients progressed to at least one prior treatment (NCT02872714, FIGHT-201); Rogaratinib 
(BAY1163877), a FGFR 1-4 inhibitor, in a phase II/III trial in patients progressed to at least one 
platinum-containing regimen (NCT03410693). 
Moreover, FGFR inhibitors are being evaluated in combinations with PD-1/PD-L1 inhibitors. A 
study by Sweis et al. showed that FGFR3 pathways were activated in non-T-cell-inflamed UC, 
characterized by an absence of intratumoral T cells, thus identifying a potential targetable pathway 
that could help to overcome tumor-intrinsic immunotherapy resistance [58]. The updated results of 
the interim analysis of the phase II study FIERCE-22 (NCT03123055) evaluating the combination of 
the FGFR3 inhibitor vofatamab (a human IgG1 monoclonal antibody directed against FGFR3) in 
combination with pembrolizumab in 28 patients (20 wild-type) progressed following 
platinum-based chemotherapy have been presented at European Society for Medical Oncology 
(ESMO) Congress 2019: the combination therapy resulted to be well tolerated with encouraging ORR 
(29.6%) and a median PFS is 4.7 months [144]. 
Combination of FGFR inhibitors and ICIs currently under investigation in ongoing clinical trials 
are: Rogaratinib ± atezolizumab in first-line treatment of cisplatin ineligible patients with FGFR 1-3 
alterations (NCT03473756, FORT-2); pemigatinib ± pembrolizumab versus standard of care 
(chemotherapy or pembrolizumab) in first-line treatment cisplatin-ineligible patients with FGFR3 
mutation or rearrangement (NCT04003610, FIGHT-205); derazantinib (a FGFR 1-3 inhibitor) ± 
atezolizumab in cisplatin ineligible patients with FGFR alteration in first-line or progressed to prior 
FGFR inhibitor treatment (NCT04045613); erdafitinib plus cetrelimab (an IgG4 monoclonal antibody 
directed against PD-1) in pretreated (phase Ib) or previously untreated cisplatin-ineligible patients 
(phase II) (NCT03473743). 
Other target therapy treatments under evaluation are PI3K/mTOR inhibitors since this pathway 
resulted to be frequently altered in UC, as already discussed [46]. mTOR inhibitors and PI3K 
inhibitors are currently being tested alone (everolimus: NCT00805129, sapanisertib: NCT03047213, 
Buparlisib: NCT01551030), and in combination with anti-PD-1/PD-L1 (nivolumab plus 
nab-rapamycin: NCT03190174, durvalumab plus vistusertib: NCT02546661, module E) or 
chemotherapy (paclitaxel plus TAK-228: NCT03745911). 
Another interesting pathway being investigated is targeting human epidermal growth factor 
receptor 2 (HER2, ERBB2) considering that mutation or amplification of ERBB2 gene has been 
identified in 9% of MIBC [46]. Trastuzumab deruxtecan is an ADC composed of trastuzumab, a 
monoclonal antibody targeting HER2 conjugated to deruxtecan, a derivative of the camptothecin 
analog exatecan, a DNA topoisomerase 1 inhibitor. This compound is being tested in combination 
with nivolumab in a phase I/II trial in patients with HER2 expression of IHC 1+, 2+ or 3+, progressed 
to prior platinum-based therapy (NCT03523572). RC48-ADC, an anti-HER2 monoclonal antibody, in 
under evaluation in two phase II trial in previously treated patients, one in HER2 negative (IHC 0 or 
1+, NCT04073602) and one in HER2 overexpressed tumors (IHC 2+ or 3+, NCT03809013). PRS-343, a 
bivalent, bispecific fusion protein composed of an anti-HER2 monoclonal antibody linked to a 
CD137-targeting anticalin, is being investigated in HER2 positive solid tumor malignancy, including 
UC, for which standard therapies are not available.  
Ongoing phase I/II/III trials, either recruiting or active not recruiting, of target therapies in 
advanced or metastatic UC are summarized in Table 7, while miscellanea therapies are reported in 
Table 8.
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Table 7. Ongoing phase I/II/III trials of target therapies. ORR: overall response rate. PFS: progression-free survival. OS: overall survival. 
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Table 8. Ongoing phase I/II/III trials of miscellanea therapies. ORR: overall response rate. PFS: progression-free survival. OS: overall survival. 
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4. Conclusions 
In the recent years, the treatment scenario of metastatic UC has been enriched with several new 
therapeutic options. Immunotherapy is a very promising approach for this disease, but a high 
percentage of patients are still resistant to this type of treatment. In the future years, the results of the 
ongoing trials investigating ICIs in combination with target therapy or chemotherapy will assess if 
resistance to ICIs alone can be overcome. Promising treatment approaches are FGFR inhibitors and 
enfortumab vedotin. These two treatment strategies already showed good results in monotherapy 
and combination therapies with ICIs being tested. Other compounds, such as PARP inhibitors, 
mTOR inhibitors, anti-VEGF, tyrosine kinase inhibitors, HER2 targeting therapies, either alone or in 
several types of combinations, are being investigated in clinical trials. 
The therapeutic approach to UC, which for many years has been dominated by platinum 
containing chemotherapy based on clinical and laboratory variable defining cisplatin eligibility, is 
now shifting toward a more personalized approach, based on the presence of molecular alteration 
(e.g., FGFR alterations) or PD-L1 expression. 
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